POLE and neoplasm: This study also provides a unique opportunity to conduct translational research analyses on pretreatment and post-treatment tumour tissue samples and blood samples from dMMR/MSI-H or POLE mutant CRC patients treated with the immune checkpoint inhibitor avelumab.